|
1
|
Davis GL, Dempster J, Meler JD, Orr DW,
Walberg MW, Brown B, Berger BD, O'Connor JK and Goldstein RM:
Hepatocellular carcinoma: Management of an increasingly common
problem. Proc (Bayl Univ Med Cent). 21:266–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simonetti RG, Camma C, Fiorello F, Politi
F, D'Amico G and Pagliaro L: Hepatocellular carcinoma. A worldwide
problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global Cancer Statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J
and Liu Z: Repeat hepatectomy for recurrent hepatocellular
carcinoma: A local experience and a systematic review. World J Surg
Oncol. 8:552010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee PH, Lin WJ, Tsang YM, Hu RH, Sheu JC,
Lai MY, Hsu HC, May W and Lee CS: Clinical management of recurrent
hepatocellular carcinoma. Ann Surg. 222:670–676. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanematsu T, Matsumata T, Takenaka K,
Yoshida Y, Higashi H and Sugimachi K: Clinical management of
recurrent hepatocellular carcinoma after primary resection. Br J
Surg. 75:203–206. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsujita E, Yamashita Y, Takeishi K,
Matsuyama A, Tsutsui S, Matsuda H, Toshima T, Taketomi A, Shirabe
K, Ishida T and Maehara Y: Poor prognostic factors after repeat
hepatectomy for recurrent hepatocellular carcinoma in the modern
era. Am Surg. 78:419–425. 2012.PubMed/NCBI
|
|
10
|
Ikeda K, Osaki Y, Nakanishi H, Nasu A,
Kawamura Y, Jyoko K, Sano T, Sunagozaka H, Uchino K, Minami Y, et
al: Recent progress in radiofrequency ablation therapy for
hepatocellular carcinoma. Oncology. 87 Suppl 1:S73–S77. 2014.
View Article : Google Scholar
|
|
11
|
Feng K and Ma KS: Value of radiofrequency
ablation in the treatment of hepatocellular carcinoma. World J
Gastroenterol. 20:5987–5998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Q, Kobayashi S, Ye X and Meng X:
Comparison of hepatic resection and radiofrequency ablation for
small hepatocellular carcinoma: A meta-analysis of 16,103 patients.
Sci Rep. 4:72522014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khajanchee YS, Hammill CW, Cassera MA,
Wolf RF and Hansen PD: Hepatic resection vs. minimally invasive
radiofrequency ablation for the treatment of colorectal liver
metastases a markov analysis. Arch Surg. 146:1416–1423. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu C, Liu N, Deng Q, Li X, Ma K and Bie P:
Radiofrequency ablation vs. surgical resection on the treatment of
patients with small hepatocellular carcinoma: A system review and
meta-analysis of five randomized controlled trials.
Hepatogastroenterology. 61:1722–1729. 2014.PubMed/NCBI
|
|
15
|
Nguyen T, Hattery E and Khatri VP:
Radiofrequency ablation and breast cancer: A review. Gland Surg.
3:128–135. 2014.PubMed/NCBI
|
|
16
|
van der Ploeg IM, van Esser S, van den
Bosch MA, Mali WP, van Diest PJ, Rinkes Borel IH and van
Hillegersberg R: Radiofrequency ablation for breast cancer: A
review of the literature. Eur J Surg Oncol. 33:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hiraki T, Gobara H, Iguchi T, Fujiwara H,
Matsui Y and Kanazawa S: Radiofrequency ablation as treatment for
pulmonary metastasis of colorectal cancer. World J Gastroenterol.
20:988–996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fegrachi S, Besselink MG, van Santvoort
HC, van Hillegersberg R and Molenaar IQ: Radiofrequency ablation
for unresectable locally advanced pancreatic cancer: A systematic
review. HPB (Oxford). 16:119–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McGhana JP and Dodd GD: Radiofrequency
ablation of the liver: Current status. AJR Am J Roentgenol.
176:3–16. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Navarra G, Bartolotta M, Scisca C and
Barbera A: Ultrasound-guided radiofrequency-assisted segmental
arterioportal vascular occlusion in laparoscopic segmental liver
resection. Surg Endosc. 22:1724–1728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu CH, Yu CY, Chang WC, Dai MS, Hsiao CW
and Chou YC: Radiofrequency ablation of hepatic metastases: Factors
influencing local tumor progression. Ann Surg Oncol. 21:3090–3095.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waldhauer I and Steinle A: NK cells and
cancer immunosurveillance. Oncogene. 27:5932–5943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morvan MG and Lanier LL: NK cells and
cancer: You can teach innate cells new tricks. Nat Rev Cancer.
16:7–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marcus A, Gowen BG, Thompson TW, Iannello
A, Ardolino M, Deng W, Wang L, Shifrin N and Raulet DH: Recognition
of tumors by the innate immune system and natural killer cells. Adv
Immunol. 122:91–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hagerling C, Casbon AJ and Werb Z:
Balancing the innate immune system in tumor development. Trends
Cell Biol. 25:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moretta A, Marcenaro E, Parolini S,
Ferlazzo G and Moretta L: NK cells at the interface between innate
and adaptive immunity. Cell Death Differ. 15:226–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vivier E, Raulet DH, Moretta A, Caligiuri
MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or
adaptive immunity? The example of natural killer cells. Science.
331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vivier E, Nunès JA and Vély F: Natural
killer cell signaling pathways. Science. 306:1517–1519. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xuan XY, Zhang JF, Hu GM, Li QR, Liu PP
and Du Y: Upregulated expression of NKG2D and its ligands give
potential therapeutic targets for patients with thymoma. Cancer
Gene Ther. 22:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raneros Baragaño A, Suarez-Álvarez B and
López-Larrea C: Secretory pathways generating immunosuppressive
NKG2D ligands: New targets for therapeutic intervention.
Oncoimmunology. 3:e284972014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spear P, Wu MR, Sentman ML and Sentman CL:
NKG2D ligands as therapeutic targets. Cancer Immun.
13:82013.PubMed/NCBI
|
|
32
|
Dromi SA, Walsh MP, Herby S, Traughber B,
Xie J, Sharma KV, Sekhar KP, Luk A, Liewehr DJ, Dreher MR, et al:
Radiofrequency ablation induces antigen-presenting cell
infiltration and amplification of weak tumor-induced immunity.
Radiology. 251:58–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zerbini A, Pilli M, Laccabue D, Pelosi G,
Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C and
Missale G: Radiofrequency thermal ablation for hepatocellular
carcinoma stimulates autologous NK-cell response. Gastroenterology.
138:1931–1942. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Virmani S, Harris KR, Szolc-Kowalska B,
Paunesku T, Woloschak GE, Lee FT, Lewandowski RJ, Sato KT, Ryu RK,
Salem R, et al: Comparison of two different methods for inoculating
VX2 tumors in rabbit livers and hind limbs. J Vasc Interv Radiol.
19:931–936. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fischer AH, Jacobson KA, Rose J and Zeller
R: Hematoxylin and eosin staining of tissue and cell sections. CSH
Protoc. 2008:pdb.prot49862008.PubMed/NCBI
|
|
36
|
Hoppner M, Luhm J, Schlenke P, Koritke P
and Frohn C: A flow-cytometry based cytotoxicity assay using
stained effector cells in combination with native target cells. J
Immunol Methods. 267:157–163. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Seong NJ, Yoon CJ, Kang SG, Chung JW, Kim
HC and Park JH: Effects of arsenic trioxide on radiofrequency
ablation of VX2 liver tumor: Intraarterial versus intravenous
administration. Korean J Radiol. 13:195–201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ohshima K, Suzumiya J, Shimazaki K, Kato
A, Tanaka T, Kanda M and Kikuchi M: Nasal T/NK cell lymphomas
commonly express perforin and Fas ligand: Important mediators of
tissue damage. Histopathology. 31:444–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Scheele J, Stangl R and Altendorf-Hofmann
A: Hepatic metastases from colorectal carcinoma: Impact of surgical
resection on the natural history. Br J Surg. 77:1241–1246. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cucchetti A, Piscaglia F, Cescon M,
Ercolani G and Pinna AD: Systematic review of surgical resection
vs. radiofrequency ablation for hepatocellular carcinoma. World J
Gastroenterol. 19:4106–4118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mulier S, Ni Y, Jamart J, Ruers T, Marchal
G and Michel L: Local recurrence after hepatic radiofrequency
coagulation: Multivariate meta-analysis and review of contributing
factors. Ann Surg. 242:158–171. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pawlik TM, Izzo F, Cohen DS, Morris JS and
Curley SA: Combined resection and radiofrequency ablation for
advanced hepatic malignancies: Results in 172 patients. Ann Surg
Oncol. 10:1059–1069. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng M, Chen Y, Xiao W, Sun R and Tian Z:
NK cell-based immunotherapy for malignant diseases. Cell Mol
Immunol. 10:230–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
